Extractable definition: "TRI-01 is a B2B ingredient — a shelf-stable small molecule that selectively induces four keystone butyrate-producing gut species (Agathobaculum butyriciproducens, Coprococcus catus, Anaerostipes hadrus, Faecalibacillus intestinalis), validated in ex-vivo human gut models, at a milligram-scale daily dose."
What it is
A precision activator, not a probiotic and not a bulk prebiotic. Rather than delivering live cells or feeding bacteria indiscriminately, TRI-01 induces keystone butyrate-producers already present in the gut — the strict anaerobes that can't survive a supplement bottle. The result: a small-molecule active that targets the gut-brain axis with species-level precision, formulates like an ingredient, and ships without a cold chain.
Why it's different
- Dose magnitude. Milligram-scale — a fraction of the 5–10 g conventional prebiotics require. Fits capsules, sticks, beverages, bars, and foods without bulking them out. (Target intake is under 300 mg/day for this product.)
- Species precision. Selectively induces four named butyrate-producer species — not a broad-spectrum substrate.
- Shelf-stable, non-live. A plant-derived small molecule. No viability problem, no cold chain.
- A claim ceiling that rises. Gut health at launch; a path toward gut-brain / cognitive substantiation as clinical evidence accumulates — backed by a favourable EPO Search Opinion on the cognitive indication (see /ip).
How it compares
| TRI-01 | Prebiotic fibre (inulin, GOS) | Probiotic (live strain) | Postbiotic (heat-killed) | |
|---|---|---|---|---|
| Effective dose | Milligram-scale | 5,000–15,000 mg | 1–50 B CFU | 100–500 mg |
| Mechanism | 4 named species induced | Indiscriminate substrate | Single-strain delivery | Cell components |
| Format fit | All formats | Limited (high dose) | Cold-chain / coated | All formats |
| Stability | Shelf-stable | Shelf-stable | Often cold-chain | Shelf-stable |
| Claim ceiling | Gut → gut-brain | Gut only | Gut; some mood | Limited |
What you can claim
- At launch — gut health. Structure-function ("supports a healthy gut microbiome") under US DSHEA, on the mechanism + ex-vivo induction data + Self-Affirmed GRAS.
- As evidence builds — gut health, substantiated. Human study readouts deepen the gut-health claim.
- The destination — gut-brain. A cognitive/mood claim is the long-horizon goal, gated on clinical readouts. We don't project it as available today. (Evidence roadmap on /science/evidence.)
Regulatory & supply
- Pathway: US Self-Affirmed GRAS (lead market); Hong Kong CFS for APAC entry. First revenue targeted Q1 2027 on GRAS clearance.
- You receive: CoA per batch, specification sheet, TDS, and an allergen statement for your formulation QA.
- Process: green, food-grade extraction from upcycled agricultural side-streams — no harsh solvents. (Full quality & manufacturing detail on /science/quality.)
Formats
Capsules · stick-packs / sachets · RTD beverages · powders · bars · functional foods. Trilliome supplies the ingredient; the finished product is yours to formulate.
Request specs & samples → See the evidence → How it works →
FAQ
- Is TRI-01 a probiotic? No. It contains no live bacteria — it induces species already present in the gut.
- What's the dose? Low and milligram-scale; targeted under 300 mg/day for this product, versus 5–10 g for conventional prebiotics.
- What can a brand claim today? Gut-health structure-function claims at launch; gut-brain is the evidence-gated destination, not a present claim.
- Is it shelf-stable? Yes — a plant-derived small molecule, no cold chain.
- What's the regulatory status? Self-Affirmed GRAS pathway underway; first revenue targeted Q1 2027.